{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:32:47Z","timestamp":1793817167079,"version":"4.6.1"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,10,15]]},"DOI":"10.2169\/internalmedicine.4701-20","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T22:05:11Z","timestamp":1592863511000},"page":"2499-2504","source":"Crossref","is-referenced-by-count":22,"title":["Sj\u00f6gren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer"],"prefix":"10.2169","volume":"59","author":[{"given":"Tetsuo","family":"Higashi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoki","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Naoe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaki","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: iv119-iv142, 2017."},{"key":"2","unstructured":"2. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sj\u00f6gren's syndrome (1999): availability and validity. Mod Rheumatol 14: 425-434, 2004."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76: 43-50, 2017.","DOI":"10.1136\/annrheumdis-2016-209595"},{"key":"4","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"C Calabrese","year":"2017","unstructured":"4. Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3: e000412, 2017.","journal-title":"RMD Open","ISSN":"https:\/\/id.crossref.org\/issn\/2056-5933","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Teyssonneau D, Cousin S, Italiano A. Gougerot-Sj\u00f6gren-like syndrome under PD-1 inhibitor treatment. Ann Oncol 28: 3108, 2017.","DOI":"10.1093\/annonc\/mdx531"},{"key":"6","unstructured":"6. Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82: 34-44, 2017."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Takahashi S, Chieko X, Sakai T, Hirose S, Nakamura M. Nivolumab-induced sialadenitis. Respirol Case Rep 6: e00322, 2018.","DOI":"10.1002\/rcr2.322"},{"key":"8","unstructured":"8. Narv\u00e1ez J, Juarez-Lopez P, LLuch J, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 17: 1040-1045, 2018."},{"key":"9","unstructured":"9. Ramos-Casals M, Maria A, Suarez-Almazor ME, et al. Sicca\/Sj\u00f6gren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol 37 (Suppl 118): 114-122, 2019."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Warner BM, Baer AN, Lipson EJ, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24: 1259-1269, 2019.","DOI":"10.1634\/theoncologist.2018-0823"},{"key":"11","unstructured":"11. Ortiz Brugu\u00e9s A, Sibaud V, Herbault-Barres B, et al. Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist 25: e391-e395, 2020."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren's syndrome. J Autoimmun 34: 400-407, 2010.","DOI":"10.1016\/j.jaut.2009.10.004"},{"key":"13","unstructured":"13. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18: 1039-1060, 2010."},{"key":"14","unstructured":"14. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22: 886-894, 2016."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4: 374-378, 2018.","DOI":"10.1001\/jamaoncol.2017.2925"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/20\/59_4701-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T03:43:38Z","timestamp":1602906218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/20\/59_4701-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":15,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4701-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}